57
Participants
Start Date
April 26, 2013
Primary Completion Date
February 28, 2020
Study Completion Date
February 28, 2020
Pembrolizumab 2 mg/kg
Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
Pembrolizumab 10 mg/kg
Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
Pembrolizumab 200 mg
Administered as an IV infusion on Day 1 of each 21-day cycle
Cisplatin 75 mg/m^2
Administered as an IV infusion on Day 1 of each 21-day cycle
Pemetrexed 500 mg/m^2
Administered as an IV infusion on Day 1 of each 21-day cycle
Carboplatin AUC 5 mg/mL/min
Administered as an IV infusion on Day 1 of each 21-day cycle
Carboplatin AUC 6 mg/mL/min
Administered as an IV infusion on Day 1 of each 21-day cycle
Paclitaxel 200 mg/m^2
Administered as an IV infusion on Day 1 of each 21-day cycle
Nab-paclitaxel 100 mg/m^2
Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle
Ipilimumab 1 mg/kg
Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)
Etoposide 100 mg/m^2
Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle
G-CSF (pegfilgrastim) 3.6 mg
Administered as a subcutaneous injection on Day 4 of Cycle 1
Merck Sharp & Dohme LLC
INDUSTRY